SCHEMBL1992218

SCHEMBL1992218

CN1CCC(Cn2nc(C3=C(c4c[nH]c5sccc45)C(=O)NC3=O)c3ccccc32)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 4/20 0.49
PRKCB P05771 14/20 0.45
PRKCA P17252 14/20 0.45
PRKCD Q05655 11/20 0.45
PRKCG P05129 9/20 0.45
PRKCE Q02156 9/20 0.45
PRKCH P24723 8/20 0.45
PRKCZ Q05513 3/20 0.45
CAMK2B Q13554 3/20 0.45
CAMK2G Q13555 3/20 0.45
CAMK2A Q9UQM7 3/20 0.45
SRC P12931 1/20 0.45
GSK3B P49841 9/20 0.44
KCNH2 Q12809 1/20 0.44
PRKACA P17612 1/20 0.43
PRKACG P22612 1/20 0.43
PRKACB P22694 1/20 0.43
PRKCQ Q04759 6/20 0.42
PDPK1 O15530 1/20 0.42
DYRK3 O43781 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1993511 0.92 CAMK2D (0.45) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1996421 0.91 CAMK2D (0.50) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1997361 0.91 CAMK2D (0.45) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1995677 0.91 CAMK2D (0.49) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1994915 0.91 PRKACA (0.55) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1990609 0.90 CAMK2D (0.44) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1990076 0.90 CAMK2D (0.48) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1991812 0.89 CAMK2D (0.45) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1998189 0.89 CAMK2D (0.45) CAMK2DPRKCBPRKCAPRKCDPRKCG
SCHEMBL1990379 0.89 CAMK2D (0.45) CAMK2DPRKCBPRKCAPRKCDPRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO CAMK2D 2963/4885PRKCB 3335/4885PRKCA 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.